| Structural highlights
Publication Abstract from PubMed
(1,1-Dioxo-2H-[1,2,4]benzothiadiazin-3-yl) azolo[1,5-a]pyridine and azolo[1,5-a]pyrimidine derivatives have been investigated as potential anti-HCV drugs. Their synthesis, HCV NS5B polymerase inhibition, and replicon activity are discussed.
HCV NS5B polymerase inhibitors 2: Synthesis and in vitro activity of (1,1-dioxo-2H-[1,2,4]benzothiadiazin-3-yl) azolo[1,5-a]pyridine and azolo[1,5-a]pyrimidine derivatives.,Wang G, Lei H, Wang X, Das D, Hong J, Mackinnon CH, Coulter TS, Montalbetti CA, Mears R, Gai X, Bailey SE, Ruhrmund D, Hooi L, Misialek S, Rajagopalan PT, Cheng RK, Barker JJ, Felicetti B, Schonfeld DL, Stoycheva A, Buckman BO, Kossen K, Seiwert SD, Beigelman L Bioorg Med Chem Lett. 2009 Aug 1;19(15):4480-3. Epub 2009 May 9. PMID:19500983[1]
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
See Also
References
- ↑ Wang G, Lei H, Wang X, Das D, Hong J, Mackinnon CH, Coulter TS, Montalbetti CA, Mears R, Gai X, Bailey SE, Ruhrmund D, Hooi L, Misialek S, Rajagopalan PT, Cheng RK, Barker JJ, Felicetti B, Schonfeld DL, Stoycheva A, Buckman BO, Kossen K, Seiwert SD, Beigelman L. HCV NS5B polymerase inhibitors 2: Synthesis and in vitro activity of (1,1-dioxo-2H-[1,2,4]benzothiadiazin-3-yl) azolo[1,5-a]pyridine and azolo[1,5-a]pyrimidine derivatives. Bioorg Med Chem Lett. 2009 Aug 1;19(15):4480-3. Epub 2009 May 9. PMID:19500983 doi:10.1016/j.bmcl.2009.05.022
|
